In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on Akili (AKLI – Research Report). The company’s shares closed last Friday at $0.43.
According to TipRanks, Rhyee is a 4-star analyst with an average return of 3.7% and a 50.46% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Charles River Labs, Cardinal Health, and CVS Health.
Akili has an analyst consensus of Strong Buy, with a price target consensus of $3.25.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.20 and a one-year low of $0.33. Currently, Akili has an average volume of 44.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akili (AKLI) Company Description:
Social Capital Suvretta Holdings Corp I is a blank check company.
Read More on AKLI:
